The report of this judgment made me laugh out loud several times. Mr Justice Holman twice describes proceedings as “bizarre”. A key confidentiality agreement with Dr Kanis could not be found. “Perceived conflicts of interest” led the removal of Dr Kanis from NICE’s Guideline Development Group. Dr Kanis went on to make a statement expressly […]
Category: James Raftery’s NICE blogs
NICE and the influenza antivirals for healthy adults – No, again and again and again
NICE’s latest technology appraisal of the flu antiviral drugs (amantadine, oseltamivir and zanamivir), published in February 2009 marks the sixth time these drugs have been considered. The timelines are shown below. […]
James Raftery on NICE’s cost per QALY threshold: does the public have a view?
One approach to setting NICE’s cost per QALY threshold might be to survey the public. In 2003 NICE and the Department of Health did just that, with a study “assessing the feasibility of estimating the value that the UK population might attach to a QALY.” […]
James Raftery on a greater role for industry in NICE’s cost per QALY?
In December 2008 the Department of Health in England published the Pharmaceutical Price Regulation Scheme. It describes how the scheme will operate for at least five years from 2009. The previous scheme was to run to 2010 but the UK government withdrew it in February 2008 following a critical report from the Office of Fair Trading (OFT). […]
James Raftery: End of life drugs – what premium? Pt 2
Having recommended NHS use of sunitinib for renal cancer, the appraisal committee of the National Institute of Health and Clinical Excellence (NICE) issued separate draft guidance for consultation, recommending against the use of bevacizumab, sorafenib, and temsirolimus, which – along with sunitinib – had been rejected for renal cancer in 2008. […]
James Raftery: End of life drugs—what premium? Pt 1
The National Institute for Health and Clinical Excellence (NICE), the UK drugs watchdog, is currently appraising the use of four drugs—bevacizumab, sorafenib, sunitinib, and temsirolimus—for the treatment of advanced or metastatic renal cell cancer. NICE has decided to split this appraisal in two, in order to get guidance out to the NHS as quickly as […]